The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication.
Thursday’s announcement will paint a clearer picture of the company’s position, as the stock hasn’t fully recovered from the February collapse that was caused by a profit warning.
Tate & Lyle made the strategic decision to sell off its loss making sugar refining operation in order to go into the food ingredients business. Splenda sweetener is one of the company’s bestselling brands and sucralose, the main ingredient in Splenda, has been accepted by a number of international food safety bodies, but concerns still linger over its long-term side effects. Tate & Lyle’s products have sold well in the Asia and South America but poor soft drink sales in the US have weighed on sentiment.
The market consensus is for an operating profit of £353 million but the company has stated it should come in at £329 million, which is unchanged from last year’s profit.
The share price has yet to fill the gap between 783 and the recent high of 721. If the results on Thursday are weak we could have renewed takeover speculation by its Chinese competitors, which could drive the share price to 783. The stock has found support at the 640 level.